Association of PICALM Gene Polymorphisms with Alzheimer's Disease: Evidence from an Updated Meta-Analysis

Fang-Fang Zeng1, Jun Liu2, Hong He3

  • 1Department of Epidemiology, School of Medicine, Jinan University, Guangzhou 510630, China.

Abstract

Insights

This meta-analysis found that PICALM gene polymorphisms rs3851179 and rs541458 are associated with a reduced risk of Alzheimer's disease (AD). No association was found for the rs592297 polymorphism.

Area of Science:

  • Genetics and Genomics
  • Neuroscience
  • Epidemiology

Background:

  • Alzheimer's disease (AD) susceptibility is influenced by genetic factors.
  • Previous studies on PICALM gene polymorphisms (rs3851179, rs541458, rs592297) and AD risk yielded inconclusive results.

Approach:

  • A comprehensive meta-analysis was conducted using data from multiple databases (PubMed, Embase, Web of Science, CNKI).
  • Summary Odds Ratios (ORs) with 95% Confidence Intervals (CIs) were calculated using a random effects model.
  • Subgroup and meta-regression analyses were performed to explore heterogeneity and identify specific population effects.

Key Points:

  • The meta-analysis included 9,017 cases and 15,448 controls for rs3851179, 8,077 cases and 12,022 controls for rs541458, and 2,106 cases and 2,234 controls for rs592297.
  • rs3851179 (A allele) and rs541458 (C allele) showed a significant inverse association with AD risk.
  • The protective effect of rs541458 was primarily observed in Caucasian populations.

Conclusions:

  • PICALM gene polymorphisms rs3851179 and rs541458 are associated with a decreased risk of Alzheimer's disease.
  • The rs592297 polymorphism showed no significant association with AD risk in this meta-analysis.
  • Further studies with larger sample sizes are needed to confirm the null association for rs592297.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...